NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 8 min 1 sec ago
Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and their Functions (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-RM-18-036 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. This FOA solicits development of new, more easily accessible tools, reagents, and technologies to facilitate identification, tracking, manipulation, and analysis of glycans with their biological binding partners and determine their functions. This initiative may build on efforts that interface with existing technologies and procedures to make them easier to access and use. As applicable, efforts must consider: factors for scale-up; efforts to make instrumentation broadly accessible and cost-effective for the end-user; and compatibility of data generated with integration into existing databases. While this FOA seeks development of new or more robust tools and technologies, the related RFA RM-18-037 is a solicitation for adaptation of existing technologies for simplification and ease of accessibility to the greater biomedical research community.
Innovative Adaptations to Simplify Existing Technologies for Manipulation and Analysis of Glycans (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-RM-18-037 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. This FOA solicits development of innovative adaptations of existing technologies to enable their use for readily identifying, manipulating, or analyzing glycans and their biological binding partners. This may encompass the adaptation of commonly used laboratory-based or computational tools to enable their facile application to glycoscience for the first time, as well as the adaptation of tools presently used by specialists in glycoscience to make them significantly more straightforward and accessible for non-specialists. It is possible that a project might simplify a current specialized approach by migrating it to a more commonly used platform, developing automation for data acquisition and interpretation, or redesigning the present tool to make it easier to use. This announcement differs from the related RFA RM-18-036 which solicits new or more effective tools or technologies, thus representing an expansion of existing technologies.
Notice of Expiration of PAR-18-866 "Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed)"
Notice NOT-AR-19-014 from the NIH Guide for Grants and Contracts
Reminder of Required Letter of Support for PAR-17-190 "Maximizing Investigators' Research Award for Early Stage Investigators (R35)"
Notice NOT-GM-18-046 from the NIH Guide for Grants and Contracts
Notice of Change of Receipt Date for RFA-EY-18-001 "BRAIN Initiative: New Concepts and Early - Stage Research for Large - Scale Recording and Modulation in the Nervous System (R21 Clinical Trial Not Allowed)"
Notice NOT-NS-18-088 from the NIH Guide for Grants and Contracts
Notice of Change of Receipt Date for RFA-NS-18-019 "BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)"
Notice NOT-NS-18-086 from the NIH Guide for Grants and Contracts
Notice of Change of Receipt Date for RFA-NS-18-020 "BRAIN Initiative: New Technologies and Novel Approaches for Large-Scale Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)"
Notice NOT-NS-18-087 from the NIH Guide for Grants and Contracts
Human Islet Research Network - Consortium on Human Islet Biomimetics (HIRN-CHIB) (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-011 from the NIH Guide for Grants and Contracts. This FOA invites new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components. CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans.
Notice of Expiration of RFA-ES-16-004 "Maintain and Enrich Resource Infrastructure for Existing Environmental Epidemiology Cohorts (R24)"
Notice NOT-ES-18-009 from the NIH Guide for Grants and Contracts
Notice of Correction to Eligibility Information in RFA-AG-19-010 "Alzheimer Centers for Discovery of New Medicines (U54 Clinical Trial Not Allowed)"
Notice NOT-AG-18-025 from the NIH Guide for Grants and Contracts
Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Required)
Funding Opportunity RFA-CA-19-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary cancers, with the goal of improving prevention and detection.
Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (X02 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-900 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This X02 pre-application and the companion R61/R33 (RFA-AR-19-013) encourage applications related to musculoskeletal diseases. The X02 pre-application is the highly recommended (not required) first step in the application process for the companion R61/R33 (RFA-AR-19-013). Potential applicants should read both FOAs. Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program will be notified of the opportunity to submit an R61/R33 application under RFA-AR-19-013.
Notice of NHLBI Participation in PA-18-592 "Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)"
Notice NOT-HL-18-647 from the NIH Guide for Grants and Contracts
Elucidating the Role of the Autonomic Nervous System in Peripheral Metabolism and Metabolic Disease through the Application of Novel Tools and Methodologies (RC2 Clinical Trial Optional)
Funding Opportunity PAR-18-898 from the NIH Guide for Grants and Contracts. NIDDK utilizes High Impact, Interdisciplinary Science (RC2) grants to support projects that will lay the foundation for new fields of investigation within the mission of NIDDK. The RC2 is envisioned to use an interdisciplinary approach to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This targeted FOA specifically seeks to generate scientific advancements addressing the role of the autonomic nervous system in the regulation of peripheral metabolism and its role in diabetes, obesity and related metabolic disease. Interdisciplinary teams may propose to develop resources in the form of novel tools or methodologies that when applied to the autonomic nervous system will contribute to elucidating its functional role in metabolism. Alternatively, teams may focus on novel approaches to address specific knowledge gaps or scientific questions that will significantly contribute to our understanding of role of the autonomic nervous system in metabolism with the goal of accelerating scientific progress in the treatment and prevention of metabolic disease.
Funding Opportunity RFA-MH-19-240 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits proposals for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function. These projects should focus on behavior in humans and test computational models in healthy subjects. For future applications, NIMH is particularly interested in behavioral measures, models, and parameters that have the potential for back-translation from humans to animals, especially for pre-clinical therapeutics development. NIMH is also interested in models that can be extended to clinical populations in the future.
Notice of Expiration of PA-18-891, Elucidating the Role of the Autonomic Nervous System in Peripheral Metabolism and Metabolic Disease through the Application of Novel Tools and Methodologies (RC2 Clinical Trial Optional)
Notice NOT-DK-18-022 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-18-012 from the NIH Guide for Grants and Contracts. Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits a single application for the continuation of the AIDS and Cancer Specimen Resource (ACSR). The eligible applicant institutions (which are the two current NCI-supported ACSR lead institutions) are expected to maintain the cooperative group structure and the activities of the ACSR. The primary objective of the ACSR will be to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated demographic data from patients with human immunodeficiency virus (HIV)-associated malignancies. In addition to serving acquired immunodeficiency syndrome (AIDS) and cancer researchers at large, the ACSR will specifically provide biorepository functions for another NCI supported initiative, the AIDS Malignancy Consortium (AMC). The AMC performs clinical trials research in the treatment and prevention of HIV-associated malignancies in the United States and Sub-Saharan Africa. As the AMC is currently expanding its agenda to include Latin America, it is expected that the ACSR will collaborate with the AMC to develop regional biorepository support for AMC activities in Latin American countries. The continuing ACSR must have appropriate strategies and capabilities to address several high priority areas of specimen acquisition including specific types of cancer (AIDS-defining as well as non-AIDS defining), types of biospecimens and accompanying clinical data, and biospecimens from geographic areas of interest.
Funding Opportunity PAR-18-895 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity is to support studies with a focus on developing drug delivery strategies that target the Central Nervous System (CNS) for better suppression of Human Immunodeficiency Virus (HIV) and reservoir reduction. Applications are sought proposing multidisciplinary efforts to enhance delivery of antiretroviral (ARV) drugs and biologics into CNS compartments, maintaining a good balance between therapeutic effect and toxicity. Collaborative research partnerships are strongly encouraged but not required.
Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)
Funding Opportunity PAR-18-894 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from backgrounds underrepresented in biomedical, behavioral, clinical and social sciences research. This award supports the completion of the doctoral research project.
Notice of the NINDS' Participation in PAR-18-296 and interest in Clinical Trial readiness applications for Frontotemporal Degeneration (FTD) by the National Institute on Aging and the National Institute of Neurological Disorders and Stroke.
Notice NOT-NS-18-082 from the NIH Guide for Grants and Contracts
NIH Funding Opportunities
- Limited Competition: RCMI Research Coordination Network (RRCN) (U54 Clinical Trial Not Allowed)
- NLM Information Resource Grants to Reduce Health Disparities (G08 Clinical Trial Not Allowed)
- Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 Clinical Trial Not Allowed)
- Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 (Collab) Clinical Trial Not Allowed)
- Notice of the Publication of an NIH Proposal to Amend the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules to Streamline Oversight of Human Gene Transfer Protocols